New Biotech Initiative Linked to Elizabeth Holmes' Partner
Elizabeth Holmes, the former CEO of Theranos, is currently serving time due to her involvement in financial deception regarding her revolutionary blood-testing firm. Despite being incarcerated, Holmes is providing advice to her partner, Billy Evans, who has garnered substantial funds for an emerging health technology startup.
The new venture, identified as Haemanthus, aims to deploy artificial intelligence in developing a product for medical testing. Although the company has not been formally unveiled, insiders reveal that it draws its name from the Latin term meaning 'blood flower.'
Billy Evans, while steering this new project with financial backing, has received support and guidance from Holmes, though the exact scope of her role remains unspecified. The startup has a team consisting of about a dozen individuals, some of whom transitioned from Evans's previous workplace at Luminar Technologies, known for pioneering sensor technologies for autonomous vehicles.
Remarkably, Holmes's involvement in this biotech effort is notable given her past conviction related to fraud in a similar sector. While serving a federal sentence in Texas, she allegedly maintains an advisory position with Evans.
Despite her incarceration, Holmes continues to assert her innocence, contending against the fraud charges even while a federal appeals court recently upheld her conviction.
Additionally, Holmes was barred in 2018 by the SEC from holding any executive position in a publicly-traded company for a decade. However, this restriction does not impede her from engaging with privately-held enterprises, though she reportedly does not plan to occupy an official managerial role at Haemanthus.
In recent communications, Holmes has expressed aspirations to re-enter the biotechnology sphere post-incarceration and is utilizing her time in confinement to develop patents for new innovations.
Haemanthus, still in nascent stages, is reportedly employing technology that utilizes light to assist AI systems in conducting medical tests. Originally beneficial in detecting certain diseases like ALS and diverse military applications, the company intends to commercialize this technology, making it accessible and affordable outside laboratory settings.
Prospective applications of Haemanthus's technology include diagnostic testing of sweat, saliva, urine, and small blood samples. However, the exact consumer-facing product remains under development, according to a patent issued earlier this year.




Leave a Reply